Related Experiment Videos
[Clinical studies on S 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections]
S Aonuma1, K Oizumi, A Watanabe
1Department of Internal Medicine, Tohoku University.
Abstract:
S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg divided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80%. There were no side effects of abnormal laboratory findings due to administration of this drug.
Insights
Sustained-release cefaclor granules demonstrated an 80% efficacy rate in treating chronic respiratory tract infections, including bronchiectasis. This antibiotic preparation showed no adverse side effects in patients during the 14-day treatment period.
Area of Science:
- Pharmacology and Therapeutics
- Infectious Diseases
- Respiratory Medicine
Context:
- Chronic respiratory tract infections pose significant health challenges.
- Bacterial infections often complicate existing respiratory conditions like chronic bronchitis, asthma, and bronchiectasis.
- Effective antibiotic treatment is crucial for managing these complex infections.
Purpose:
- To evaluate the efficacy and safety of S 6472 granule preparation, a sustained-release cefaclor formulation.
- To assess the treatment outcomes of sustained-release cefaclor in patients with various chronic respiratory tract infections.
- To determine the incidence of adverse effects associated with this cefaclor formulation.
Summary:
- S 6472 granule preparation (sustained-release cefaclor) was administered to 15 patients with chronic respiratory infections at 750 mg daily for 14 days.
- The preparation showed an 80% efficacy rate, being effective in 12 out of 15 cases, with notable success in bronchiectasis.
- No abnormal laboratory findings or side effects were reported during the study period.
Impact:
- Sustained-release cefaclor offers a potentially effective and safe therapeutic option for chronic respiratory tract infections.
- The findings support the use of this formulation in managing bacterial infections in patients with underlying respiratory conditions.
- Further research could explore optimal dosing and patient populations for this sustained-release antibiotic.